Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904369 · ClinicalTrials.gov registry record · Phase 1
PK and PD Study of Oral F/TAF for HIV Prevention
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT02904369 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 73 participants.
The verdict
NCT02904369, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This multi-center Phase I study is designed to characterize the PK and PD of F/TAF oral tablets to assess systemic and genital tract bioavailability in healthy women. The oral tablets to be used in the study are F/TAF (200/10 mg), F/TAF (200/25 mg) and F/TDF (200/300 mg, Truvada). Samples will be obtained before, during and after dosing in two study phases.
Interventions
- DRUG Tenofovir alafenamide
- DRUG Emtricitabine
- DRUG Tenofovir disoproxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2016-10-06 |
| Est. Completion | 2017-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02904369
The ClinicalTrials.gov registry entry for NCT02904369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tenofovir alafenamide is the first listed.
NCT02904369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02904369 about?
NCT02904369 is a clinical study titled "PK and PD Study of Oral F/TAF for HIV Prevention". This multi-center Phase I study is designed to characterize the PK and PD of F/TAF oral tablets to assess systemic and genital tract bioavailability in healthy women. The oral tablets to be used in the study are F/TAF (200/10 mg), F/TAF (200/25 mg) and F/TDF (200/300 mg, Truvada). Samples will be ob...
What is the current status of trial NCT02904369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2016-10-06. Estimated completion is 2017-11-21.
What interventions are being tested in trial NCT02904369?
The interventions under investigation include: Tenofovir alafenamide (DRUG), Emtricitabine (DRUG), Tenofovir disoproxil (DRUG).
Who is sponsoring clinical trial NCT02904369?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.